A 021311

Drug Profile

A 021311

Latest Information Update: 10 Sep 1999

Price : $50

At a glance

  • Originator Yung Shin Pharmaceutical
  • Class Antihyperlipidaemics; Antiplatelets
  • Mechanism of Action Platelet aggregation inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Atherosclerosis; Thrombosis

Most Recent Events

  • 10 Sep 1999 No-Development-Reported for Thrombosis in Taiwan (Unknown route)
  • 10 Sep 1999 No-Development-Reported for Atherosclerosis in China (Unknown route)
  • 28 Apr 1997 A preclinical study in a rabbit model of atherosclerosis has been added to the Hyperlipidaemia pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top